EP0594725A1 - Yolk sac stem cells - Google Patents
Yolk sac stem cellsInfo
- Publication number
- EP0594725A1 EP0594725A1 EP92915474A EP92915474A EP0594725A1 EP 0594725 A1 EP0594725 A1 EP 0594725A1 EP 92915474 A EP92915474 A EP 92915474A EP 92915474 A EP92915474 A EP 92915474A EP 0594725 A1 EP0594725 A1 EP 0594725A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- yolk sac
- stem cells
- animal
- mhc class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001325 yolk sac Anatomy 0.000 title claims abstract description 249
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 58
- 210000000601 blood cell Anatomy 0.000 claims abstract description 34
- 210000004369 blood Anatomy 0.000 claims abstract description 25
- 239000008280 blood Substances 0.000 claims abstract description 25
- 230000003394 haemopoietic effect Effects 0.000 claims abstract description 15
- 210000000777 hematopoietic system Anatomy 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 48
- 241001465754 Metazoa Species 0.000 claims description 39
- 238000001727 in vivo Methods 0.000 claims description 33
- 238000000338 in vitro Methods 0.000 claims description 22
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 20
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 20
- 230000000735 allogeneic effect Effects 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 210000004291 uterus Anatomy 0.000 claims description 13
- 230000035935 pregnancy Effects 0.000 claims description 12
- 108010002386 Interleukin-3 Proteins 0.000 claims description 10
- 102000000646 Interleukin-3 Human genes 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 10
- 241000283707 Capra Species 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 102000043129 MHC class I family Human genes 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108091054437 MHC class I family Proteins 0.000 claims description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 102000000588 Interleukin-2 Human genes 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 8
- 230000001413 cellular effect Effects 0.000 claims 5
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 306
- 230000007774 longterm Effects 0.000 abstract description 28
- 239000000427 antigen Substances 0.000 abstract description 26
- 108091007433 antigens Proteins 0.000 abstract description 26
- 102000036639 antigens Human genes 0.000 abstract description 26
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract description 21
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract description 21
- 238000002560 therapeutic procedure Methods 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 210000000265 leukocyte Anatomy 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 6
- 230000002950 deficient Effects 0.000 abstract description 5
- 230000036737 immune function Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 238000012512 characterization method Methods 0.000 abstract description 3
- 238000010276 construction Methods 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000009169 immunotherapy Methods 0.000 abstract description 2
- 229960005486 vaccine Drugs 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 41
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 241001529936 Murinae Species 0.000 description 23
- 210000001185 bone marrow Anatomy 0.000 description 21
- 230000004069 differentiation Effects 0.000 description 21
- 210000002257 embryonic structure Anatomy 0.000 description 21
- 210000000952 spleen Anatomy 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 101150052863 THY1 gene Proteins 0.000 description 17
- 238000002054 transplantation Methods 0.000 description 17
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 15
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 15
- 230000011132 hemopoiesis Effects 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 12
- 210000001161 mammalian embryo Anatomy 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 210000003754 fetus Anatomy 0.000 description 11
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 10
- 229960002092 busulfan Drugs 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 238000011579 SCID mouse model Methods 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000003951 Erythropoietin Human genes 0.000 description 8
- 108090000394 Erythropoietin Proteins 0.000 description 8
- 229940105423 erythropoietin Drugs 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 8
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 238000010322 bone marrow transplantation Methods 0.000 description 7
- 210000004748 cultured cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 206010068051 Chimerism Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 210000002798 bone marrow cell Anatomy 0.000 description 5
- 230000013020 embryo development Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 102000054766 genetic haplotypes Human genes 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000003593 megakaryocyte Anatomy 0.000 description 4
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 229950002929 trinitrophenol Drugs 0.000 description 4
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010045198 H-2 Antigens Proteins 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 108700005092 MHC Class II Genes Proteins 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000000998 lymphohematopoietic effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000606125 Bacteroides Species 0.000 description 2
- 238000011735 C3H mouse Methods 0.000 description 2
- -1 CSF's Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 210000003785 decidua Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000005868 ontogenesis Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002023 somite Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108700005089 MHC Class I Genes Proteins 0.000 description 1
- 101000962498 Macropis fulvipes Macropin Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 101710087603 Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 102000015215 Stem Cell Factor Human genes 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention is directed to yolk sac stem cells.
- it relates to the characterization, culturing, and uses of yolk sac stem cells for hematopoietic reconstitution and therapy.
- Yolk sac stem cells isolated from the early embryonic yolk sac prior to blood island formation exhibit a homogeneous morphology and a primitive cell surface phenotype without the expression of mature leukocyte markers and major histocompatibility complex encoded antigens.
- the cells can be cultured and expanded long-term without alteration of their pluripotency.
- yolk sac stem cells may have a wide range of applications including but not limited to the reconstitution of a destroyed or deficient human hematopoietic system, and the construction of large and small animal models for the production of human blood cells, human antibodies, and testing of human diseases, immune function, vaccines, drugs and immunotherapy.
- a multipotential stem cell population is capable of giving rise to blood cells of diverse morphology and function (Golde, 1991, Scientific American, December:86) . Since blood cell formation is first detectable in the embryonic yolk sac early in embryogenesis, it has been hypothesized that pluripotent hematopoietic stem cells may be present within the yolk sac, but the characteristics of such cells are still poorly understood and such cells have not heretofore been identified (Moore and Metcalf, 1970, 18:279). During fetal development, the stem cells migrate to the fetal liver where they reside temporarily, and eventually move to give rise to the bone marrow which is the permanent site of blood cell formation in the adult.
- HEMATOPOIETIC STEM CELLS A pluripotent stem cell is believed to be capable of self-renewal and differentiation into blood cells of various lineages including lymphocytes, granulocytes, acrophages/monocytes, erythrocytes and megakaryocytes (Ikuta et al., 1992, Ann. Rev. Immunol. 10:759) .
- the mechanism by which a stem cell commits to a specific cell lineage has not been fully elucidated.
- the mechanisms involved in stem cell replication without differentiation are also unknown. However, it is clear that such events must, in part, be influenced by a variety of growth and differentiation factors that specifically regulate hematopoiesis.
- EPO erythropoietin
- G/M-CSF granulocyte/macrophage colony stimulating factor
- G-CSF granulocyte colony-stimulating factor
- M-CSF macrophage colony-stimulating
- IL-1 to IL-12 interleukin 1-12
- SCF stem cell factor
- hematopoiesis An understanding of hematopoiesis is critical to the therapy of hematopoietic disorders.
- Neoplastic transformation, immunodeficiency, genetic abnormalities, and even viral infections all can affect blood cells of different lineages and at different stages of development.
- basic knowledge of blood cell development has contributed to the success of bone marrow transplantation in the treatment of certain forms of hematopoietic malignancies and anemias.
- Bone marrow stem cells are present at extremely low concentrations, and they may not be at the earliest stage of differentiation.
- An impediment in bone marrow transplantation is the need for matching the major histocompatibility complex (MHC) between donors and recipients through HLA tissue typing techniques. Matching at major loci within the MHC class I and class II genes is critical to the prevention of rejection responses by the recipient against the engrafted cells, and more importantly, donor cells may also mediate an immunological reaction to the host tissues referred to as graft versus host disease. In order to facilitate graft acceptance by the host, immunosuppressive agents often have been employed, which render the patients susceptible to a wide range of opportunistic infections.
- MHC major histocompatibility complex
- the donor cells were shown to induce hematopoiesis. Both of these n vivo studies utilized freshly isolated cells from mouse embryos, and there was no suggestion that long-term cultured and expanded embryonic yolk sac cells could retain their pluripotency. Such methods involved diffusion chambers embedded within the species of origin of the yolk sac tissue (Symann et al. , Exp. Hemat. 6:749, 1978) or methods that led to in vitro malignant transformation of the yolk sac cells. For example, long-term yolk sac cell lines were established from day 10-13 mouse embryos, and they were shown to give rise to tumor cells at high frequency (Globerson et al., 1987, Differentiation 36:185). Therefore, the potential of tumor formation renders such long-term cultured cells undesirable for use in reconstitution therap .
- MHC is a highly polymorphic complex of genes (Bach and Sachs, 1987, New Eng. J. Med. 317:489). It was first discovered by its close association with the phenomenon of transplantation rejection of tissue grafts. Subsequent studies conclusively demonstrated that antigens encoded by MHC class I genes are the major targets of transplantation rejection responses. Such antigens are expressed by- all somatic cells.
- MHC class II genes encode molecules on a limited array of cells, most of which are related to — o —
- the hematopoietic system can also elicit reactions by allogeneic immune cells.
- H-2 antigens first appeared on day 7 embryos which could provoke a strong immune reaction, but the latter suggested that these antigens did not make an appearance in utero until day 9 or later.
- MAMMALS 219 Bosset and Wild, eds., Cambridge U.:1975).
- Heyner reported that H-2 antigens were detectable in day 7 mouse embryos (Heyner, 1973, Transplantation 16:675).
- mouse yolk sac cells obtained at day 9 of gestation were shown to be capable of generating a graft-versus-host response in vitro (Hofman and Globerson, 1973, Eur. J. Immunol. 3:179).
- the present invention relates to yolk sac stem cells, a method of isolating and culturing yolk sac stem cells, and a method of using the cultured yolk sac cells for reconstituting an allogeneic or xenogeneic hematopoietic system.
- the invention is based, in part, on Applicants 1 discovery that the murine yolk sac, isolated from mouse embryos prior to visible blood island formation, contains a homogeneous population of cells that are CD34 + , Thy-1 ⁇ , MHC class I- and class II-.
- Such cells can be expanded in number by long-term in vitro culture with minimal differentiation, and can give rise to mature blood cells of diverse lineages when subsequently treated with the appropriate hematopoietic growth and differentiation factors.
- the long-term cultured cells also can mature into functionally competent blood cells in vivo, capable of mediating antigen-specific immune responses, repopulating lympho-hematopoietic organs, and prolonging survival of animals with a destroyed hematopoietic system.
- the yolk sac cells of the invention can be successfully transplanted into allogeneic fetuses in utero and into non-immunosuppressed xenogeneic hosts and since these cells do not induce graft-versus-host and host-versus-graft reactions, transplantation will result in tissue chimerism.
- the invention is described by way of examples in which murine yolk sac cells are isolated, and their cell surface phenotype is characterized.
- the homogeneous population of yolk sac cells is expanded in long-term culture, and shown to retain pluripotency in vitro and in vivo.
- a wide variety of uses for the yolk sac cells are encompassed by the invention described herein.
- FIG. 1 A schematic drawing of the appearance of mouse embryos around day 7 and day 8.5 of gestation.
- FIG. 2. Murine yolk sac cells from a day 7 embryo are more homogeneous in appearance than cells from a day 8.5 embryo by flow cytometry analysis.
- FIG. 3 Murine yolk sac cells from a day 7 embryo express CD34 but not Thy-1, MHC class I and class II antigens.
- FIG. 4 Cultured yolk sac cells can differentiate into mature blood cells in vitro, including (4A) monocytes, (4B) megakaryocytes, (4C) erythrocytes, and (4D) lymphocytes.
- FIG. 5 Yolk sac cells recovered from recipient mouse spleens following n vivo transfer demonstrate the expression of mature leukocyte antigens by donor cells.
- FIG. 6 Hemagglutination of red blood cells coated with antigens (FIG. 6A, lipopolysaccharide, and FIG. 6B, human serum albumin) by sera of immunodeficient mice treated with yolk sac cells, demonstrating restoration of immune function by yolk sac cells in vivo.
- FIG. 6A lipopolysaccharide
- FIG. 6B human serum albumin
- FIG. 7 Cultured yolk sac cells repopulate the spleens of chemically-ablated mice and give rise to colony-forming units in vivo; (7A) A comparison between a chemo-ablated mouse spleen and a fully repopulated spleen; (7B) A repopulated spleen at day 7 post-yolk sac treatment; (7C) A populated spleen at day 14 post yolk-sac treatment.
- FIG..8 In utero injection of yolk sac cells into allogenic mice leads to tissue chimerism in new born mice.
- FIG. 9 Survival and differentiation of long-term cultured murine yolk sac cells in a sheep and a goat which had received multiple high doses of yolk sac cells.
- the present invention relates to yolk sac stem cells, to methods of isolating and culturing the yolk sac stem cells, and to methods of using the yolk sac stem cells.
- the specific procedures and methods described herein are exemplified using murine yolk sac cells, they are merely illustrative for the practice of the invention. Analogous procedures and techniques are equally applicable to all mammalian species, including human subjects. Therefore, human yolk sac stem cells may be isolated from the embryonic yolk sac prior to blood island formation.
- the cells having the phenotype of CD34 + , Thy-1 — , and MHC class I- and II- may be cultured under the same conditions described herein, infra.
- Mammalian development may be divided into three distinct stages: the zy ote, from fertilization to cleavage; the embryo, from cleavage to the formation of all somites; and the fetus, from the formation of the last somite until birth.
- This invention takes advantage of the unique properties of embryonic yolk sac cells after their course of development is determined, but before they have lost either immuno-incompetency or the ability to proliferate rapidly. It is known that when completely undifferentiated cells of the blastula or morula are transplanted into a developed animal, they produce tumors. These totipotent, tumorigenic cells are of no value for in vivo reconstitution therapy.
- transplant cells which have reached a stage of specialization at which they have become committed to a particular sequence of development, or lineage.
- Such cells may be used alone or to deliver genetic material, or its expression products, into a particular tissue of the body, including blood cells.
- the cells can be transplanted into a host before or after transformation with an exogenous gene of interest, and allowed to develop into the target tissue.
- Stem cells of the embryonic yolk sac offer particular advantages for hematopoietic reconstitution. Unlike the cells of the embryo, the cells of the yolk sac develop into only a small number of different tissues. Among those tissues is the hematopoietic system, which includes the red and white blood cells, and the tissue of the veins, arteries and capillaries.
- mesodermal cells in the yolk sac begin to form blood islands.
- the cells of the blood islands differentiate, the peripheral cells becoming the endothelium of the future blood vessels, and the central cells becoming first mesenchymal cells and then the red and white blood cells.
- the blood islands establish communications to form a circulatory network, which is extended into the embryo proper.
- the yolk sac cells of the subject invention do not express MHC antigens, and can mature in allogeneic and xenogeneic hosts, demonstrating their ability to escape immune rejection.
- research with bone marrow cells has depended on the use of immunocompromised hosts.
- the culture methods described herein maintain the yolk sac in their undifferentiated state, and are applicable to mass culture of yolk sac cells, providing donor cells for large numbers of recipients.
- the embryonic yolk sac is the first identifiable site of blood cell formation in ontogeny.
- the yolk sac cells travel to the fetal liver during embryogenesis and eventually migrate to the bone marrow where they reside and differentiate into mature blood cells throughout the entire adult life.
- the embryonic development of the mammalian yolk sac is rapid and occurs within a narrow time frame.
- the murine yolk sac is fully formed by day 7 of gestation, and the formation of blood is detectable in the mesenchyme of the body stalk and in neighboring areas of the yolk sac. Shortly thereafter, masses of mesenchymal cells round up and become aggregated to form blood islands. By day 8.5, extensive blood island formation in the murine yolk sac is readily visible microscopically.
- embryonic development has reached a level where fetal liver is formed and yolk sac cells begin to migrate to the - 1 ,1 dire -
- the yolk sac Upon the departure of the yolk sac stem cells, the yolk sac begins to atrophy. Similar events also occur in embryonic development of other species, but the timing of developmental events varies between different species. In humans, the yolk sac is formed by day 10 of gestation, and blood island formation occurs shortly thereafter. Thus, human yolk sac cells isolated at day 10 may be comparable to the murine cells at day 7. Since the yolk sac is where blood cell formation is first established in development and the yolk sac cells eventually reach the bone marrow to become the bone marrow hematopoietic cells, it is reasoned that the yolk sac represents the earliest site for the generation of primordial hematopoietic cell precursors. The cells have committed to the hematopoietic differentiative pathway so that they are no longer totipotent.
- yolk sac cells are still pluripotent, since they have not yet committed to a particular blood cell lineage as seen by their ability to make cells of lymphoid, myeloid, and erythroid lineages.
- yolk sac cells may be the ideal cell population for use in reconstitution therapy including, but not limited to, bone marrow transplantation.
- the primitive nature of these cells as evidenced by the absence of cell surface expression of various mature markers and MHC transplantation rejection antigens, may render these cells uniquely capable of being used as a universal donor cell population in allogeneic and even xenogeneic hosts.
- the isolation of the embryonic yolk sac may be achieved using a variety of surgical methods.
- the yolk sac of a mouse embryo is disaggregated by the use of enzymatic digestion and mechanical separation upon surgical removal.
- a gentler method of detaching the cells from the yolk sac membrane and separating them from each other is described in Section 6.2.1. in which a yolk sac is immersed in an EDTA solution which causes the cells to segregate and form a single cell suspension. This method minimizes cell lysis due to physical force and cell surface protein alteration due to enzymatic treatment. Since the establishment of blood islands in the yolk sac marks the beginning of cellular differentiation and blood cell formation, it is preferable that yolk sac cells be isolated prior to extensive blood island formation.
- the cells are grown in medium containing a relatively high concentration of serum supplement, between 15-20%.
- Various cytokines may be added to suppress differentiation of the stem cells, including but not limited to, leukemia inhibitory factor (LIF) or stem cell factor/the c-kit ligand (SCF) or SCF in combination with other cytokines such as IL-3.
- LIF leukemia inhibitory factor
- SCF stem cell factor/the c-kit ligand
- IL-3 cytokines
- hematopoietic factors such as IL-3, CSF's and EPO also may be used in combination depending on the need to select for a particular cell type.
- IL-3 hematopoietic factor
- CSF's and EPO also may be used in combination depending on the need to select for a particular cell type.
- the combined use of IL-3 and EPO may assist in driving cultured yolk sac cells towards the erythroid pathway.
- the maintenance of cells at the appropriate temperature, C0 2 concentration, humidity level and the frequency of changing the culture media are within the ordinary skill of the art.
- yolk sac cells obtained from mouse embryos prior to blood island formation are more homogeneous in appearance than cells obtained at a later stage.
- yolk sac stem cells can be characterized as CD34 + , Thy-1 — , MHC class I- and MHC class II-.
- human yolk sac stem cells obtained from day 10 embryos should display an identical cell surface phenotype.
- CD34 and Thy-1 markers previously have been demonstrated to be associated with bone marrow hematopoietic stem cells (Spangrude et al. , 1988, Science 241:58) . While CD34 expression declines as stem cells differentiate and mature, the presence of Thy-1 is retained and its density increased in certain mature blood cells, particularly T-lymphocytes. The finding that yolk sac stem cells are positive for CD34 expression is consistent with these cells being stem cells. However, the absence of Thy-1 expression suggests that yolk sac cells may represent an earlier cell population than the bone marrow stem cells which express low levels of Thy-1 in the bone marrow microenvironment.
- tissue typing is currently a routine clinical procedure in ensuring graft acceptance in human transplant patients by matching the donors and recipients at the major MHC genetic loci.
- the absence of MHC antigens on the yolk sac cell surface strongly suggests the possibility of using such cells as universal donors in hematopoietic reconstitution therapy, alleviating the need of tissue typing and the restrictive use of only MHC-matched tissues as donor cells.
- the development of adoptively transferred yolk sac cells in the environment of the host may lead to specific tolerance between the host and donor cells for each other, causing a diminution of the potential for inducing graft-versus-host and host-versus-graft reactions.
- yolk sac phenotype is seen with the vast majority of cells isolated from day 7 murine embryos. Therefore, early isolation of yolk sac cells provides for a highly homogeneous and enriched population of stem cells. This is in contradistinction to the purification procedure needed for murine bone marrow hematopoietic stem cells which are of CD34 + and Thy-1 + phenotype. Such cells must be isolated and enriched by a series of selection steps, as they constitute only less than 0.1% of the total cells in the bone marrow (Spangrude et al., 1991, Blood 78:1395). On the other hand, yolk sac stem cells can be obtained in an essentially homogeneous state without requiring additional purification, and such cells retain their phenotype and functional activity during long-term in vitro growth.
- LPS lipopolysaccharide
- HSA human serum albumin
- the high titer of LPS specific antibodies in the sera of yolk sac cell-bearing beige nude xid mice after LPS immunization indicates the presence of functionally competent antibody producing cells, i.e., B lymphocytes and plasma cells.
- HSA which is a T cell dependent antigen, elicited a weaker yet detectable specific antibody production in mice. Since the anti-HSA antibody response requires T cell help which, in turn, is first activated by antigen- presenting cells such as macrophages, this result provides evidence for the presence of mature and functional T cells, B cells, and macrophages which co ⁇ operate and interact in the generation of antibodies.
- yolk sac cells may be useful as universal donor cells in various mammalian species, including humans.
- mice may be obtained, grown in vitro and transferred into immunodeficient or immunocompromised mice. Such mice contain a human hematopoietic system and may be used for the study of human blood cell development in vivo, the " identification of novel hematopoietic growth and differentiation factors, and testing for cytotoxic and/or inhibitory compounds that affect various stages of blood cell formation as well as anti-cancer drugs.
- Hu atoMouseTM Such a chimeric mouse referred to as Hu atoMouseTM herein would be superior to the conventional SCID/Hu mouse model in which mice are reconstituted with human bone marrow stem cells because HumatoMouseTM would permit studies in the delineation of the earliest events in hematopoiesis.
- yolk sac cells may be implanted in utero into normal mouse fetuses for engraftment of human blood cells in a normal mouse environment. Such yolk sac cells may be transfected with a drug-resistance gene so as to allow subsequent selective ablation of only the host cells using the corresponding drug.
- SCID mice are not totally immunodeficient and that a small amount of restoration of immune function is correlated with the age of the mice.
- SCID mice possess detectable natural killer cell and macrophage activities. A small percentage of mice even re-acquire T and B cell function as they mature.
- conventional SCID mice may not be the most appropriate hosts for the construction of the HumatoMouseTM as their immune function may interfere with the analysis of the donor yolk sac cells.
- the steel mice possess a mutation at the steel locus which encodes SCF, a ligand for the proto-oncogene c-kit cell surface receptor.
- Mouse fetuses that are homozygous for this mutation live only to about day 15 of gestation before they are aborted due to the absence of a hematopoietic system and blood cell formation.
- human yolk sac cells may be injected into the developing homozygous fetuses in utero prior to abortion, e.g., at day 8, to reconstitute their hematopoietic function.
- the resulting neonates should have a fully humanized system with no contribution by the host as they would not normally have lived to birth.
- mice can develop into mature blood cells jLn vivo, suggesting that the cells secrete the necessary growth and differentiation factors for supporting their own development.
- a further improvement of the HumatomouseTM model includes the introduction of human growth and differentiation factor genes in the mice.
- certain of the critical cytokines for human blood cell formation are species-specific, such as SCF, and mouse molecules do not act effectively to promote growth and differentiation of human cells
- transgenic SCID or steel mice may be constructed to result in endogenous production of human cytokines of interest such as IL-3, CSF's, and SCF.
- human yolk sac cells may be transfected with murine receptor genes. The subsequent transfer of human yolk sac cells to these mice should give rise to a more complete and efficient human hematopoietic system in mice.
- graft rejection host versus graft
- graft versus host reactions may be attributed to the primitive nature of the yolk sac cells, particularly the lack of MHC antigen expression, allowing the cells and the host immune system to "learn" each other as self prior to MHC expression and thus, induce a state of specific tolerance.
- Xenogeneic transplants of solid organs have been carried out in humans in situations where there is a shortage of HLA- atched organs.
- yolk sac cells may be used to reconstitute the hematopoietic system of any mammalian species, for example, in a human patient with HIV infection, since non-human T cells cannot be infected by human HIV, this approach may serve as a means of limiting HIV infection in humans.
- Yolk sac cells may also be transfected with genes which are designed to disrupt HIV gene sequences involved in HIV replication prior to in vivo administration. Such exogenously introduced genes may encode anti-sense RNA or ribozyme molecules that specifically interfere with HIV replication.
- the induction of tolerance by the transfer of xenogeneic yolk sac cells may allow subsequent transplantation of solid organs, including but not limited to heart, liver and kidney from donor animals sharing the same genetic makeup of the yolk sac donors. This raises the possibility of using MHC-mismatched yolk sac cells not only for reconstitution purposes, but also as first step tolerogens for inducing specific tolerance in a recipient for subsequent organ transplants.
- this form of yolk sac cell transplantation may be applied in situations where a genetic defect has been detected in a fetus.
- Human or other mammalian yolk sac cells carrying a normal wild type gene or an exogenously introduced gene may be injected into the developing fetus in a routine procedure similar to that of amniocentesis in utero.
- the genetic disorders for which this approach may be applicable include, but are not limited to, sickle cell anemia, thalassemia, and adenosine deaminase deficiency.
- yolk sac cells may be used in settings where a pregnant mother is diagnosed to carry HIV, and reconstitution of the fetus with yolk sac cells may prevent viral infection of the fetus.
- yolk sac cells may be injected in a large farm animal, the blood collected, and large quantities of human proteins or cells such as red blood cells, lymphocytes, granulocytes, platelets, monoclonal antibodies and cytokines purified for clinical use.
- a protocol for the replacement of bone marrow cells in human patients requiring bone marrow transplantation may be devised using cultured human or xenogeneic yolk sac cells.
- Yolk sac cells obtained from human yolk sac at day 10 of gestation may be isolated using the procedures described herein, expanded in culture, and cryogenically preserved as donor cells for the transplant.
- Ablation of recipient patient bone marrow cells may not be required, but if it is used, it can be accomplished by standard total body irradiation (Kim, et al., Radiology, 122:523, 1977) or by chemotherapy with a variety of commonly used compounds including, but not limited to Busulfan (Tutschka, et al., Blood, 70:1382-1388, 1987), following the conventional methods.
- Yolk sac cells can be introduced into the recipient, using similar methods for bone marrow cells. Prior to in vivo transfer, yolk sac cells may be transformed with a drug- resistance gene, such as the methotrexate resistance gene.
- Murine yolk sac cells express CD34 but none of the other known leukocyte markers. It is possible that yolk sac cells express other early markers which have not yet been identified. If so, previous failure in identifying these unique molecules might be due to their decreased expression in more mature cells or even stem cells after migration to other sites out of the yolk sac. Therefore, yolk sac cells may be used to generate antibodies against their cell surface antigens in order to identify and characterize such unknown markers.
- polyclonal and monoclonal antibodies which recognize novel antigenic markers expressed by yolk sac cells.
- Various procedures known in the art may be used for the production of antibodies to yolk sac cells.
- various host animals can be immunized by injection with viable yolk sac cells, fixed cells or membrane preparations, including, but not limited to, those of rabbits, hamsters, mice, rats, etc.
- Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to
- Monoclonal antibodies to novel antigens on yolk sac cells may be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique originally described by Kohler and Milstein (1975, Nature 256, 495-497) , the more recent human B- cell hybridoma technique (Kosbor et al., 1983,
- Syngeneic, allogeneic, and xenogeneic hosts may be immunized with yolk sac cells which can be prepared in viable form, or in fixed form, or as extracted membrane fragments. Monoclonal antibodies can be screened differentially by selective binding to yolk sac cells, but not to mature macrophages, granulocytes, T, and B cells.
- Antibody fragments which contain the binding site of the molecule may be generated by known techniques.
- such fragments include but are not limited to: the F(ab') 2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragments.
- ANIMALS BALB/c, C57BL/6, beige nude X-linked immunodeficient (BNX) , and C3H/SCID mice were purchased from Jackson Laboratories (Bar Harbor, ME) — ⁇ o -•
- each uterine segment containing an embryo was aseptically removed by dissection with the aid of a dissenting microscope.
- Each embryo surrounded by decidua capsularis was transferred to another petri dish containing PBS plus penicillin-streptomycin.
- the decidua capsularis was opened with watchmaker's forceps and each embryo transferred into an individual petri dish where yolk sac tissue was excised from the amnion, placenta, embryo, and Reichert's membrane in 0.02% EDTA in PBS at 4°C for 15-30 minutes.
- the yolk sac cells in single cell suspension were then washed in PBS before culturing.
- CULTURE CONDITIONS Disaggregated yolk sac cells were grown in alpha medium (Sigma) supplemented with 18% heat-inactivated fetal calf serum, 0.2 Mm 3-mercaptoethanol, 50 ⁇ g/ml of gentamicin and 10% LIF conditioned medium (medium of a LIF-producing cell line, Cho LIFD at 100-1000 u/ml) . Cells were grown without feeder layers on collagen or gelatin coated dishes and incubated at 37°C in 5% C0 2 in air. Media were changed every other day. 6.1.4. FLOW CYTOMETRY ANALYSIS 10 6 yolk sac cells were washed twice in cold PBS containing 0.1 BSA and sodium azide.
- the cell pellets were suspended in the same buffer containing the test antibodies at 4°C for 30 minutes. Cells were then washed in cold PBS twice and analyzed by flow cytometry. Antibodies specific for Thy-1, Ly-1, Ly-2, Mac-l, MHC class I and class II were purchased from Boehringer Mannheim. Anti-Ml/70, anti-H2 d and anti-H2 b antibodies were purchased from Pharmingen (San Diego, CA) . Anti-CD34 was used as hybridoma supernatant.
- INDUCTION OF YOLK SAC DIFFERENTIATION BALB/c yolk sac cells were grown to approximately 50% confluency in medium containing LIF. The cells were harvested, washed and medium containing growth factors was added. Growth factors used were: LIF (100-1000 U/ml) , SCF (50 U/ml) , EPO (1-25 U/ml) , IL-2 (10-200 U/ml) , and IL-3 (10-200 U/ml) in various combinations. The medium was changed every 2 days until confluency was reached, at which time the yolk sac cells were passed 1:4 into new gelatinized 35 mm culture dishes. At day 5, and 21, cells were prepared for blood staining. Day 0, 5, and 21 cells were analyzed by flow cytometry for the appearance of differentiated blood cells.
- HEMAGGLUTINATION ASSAY Lipopolysaccharide (LPS) conjugated to trinitrophenol (TNP) and human serum albumin (HSA) conjugated to TNP were injected at 20 ⁇ g/mouse intraperitoneally into BNX mice and SCID mice, respectively, both of which had previously received 10 6 murine yolk sac cells intraperitoneally a month earlier. A second injection of the antigens was performed one week later, animals were bled after seven days and sera assayed for the presence of specific antibodies.
- LPS Lipopolysaccharide
- HSA human serum albumin
- SRBC Sheep red blood cells
- DNP dinitrophenol
- the yolk sac In the mouse, the yolk sac is fully formed by day 7 and blood island formation usually appears by day 8.5 of gestation. Therefore, in order to isolate homogeneous and undifferentiated yolk sac cells, mouse embryos were surgically removed prior to visible blood island formation, preferably at day 7 of gestation. The yolk sac region of the embryos was separated by excision, and the external surface of the yolk sac was immersed in cold EDTA which caused the detachment of the yolk sac cells from the membrane into a single cell suspension (FIG. 1) .
- day 7 yolk sac cells were used for all in vitro and jLn vivo studies described herein, infra.
- the freshly isolated yolk sac cells from day 7 mouse embryos were immediately examined for their cell surface expression of a number of known leukocyte markers by reactivity with monoclonal antibodies. 0 Such uncultured yolk sac cells express CD34 but not Thy-1, MHC class I and class II antigens (FIG. 3) .
- the expression of CD34 by yolk sac cells is consistent with them being primitive stem cells as CD34 is currently the earliest detectable marker on bone 5 marrow hematopoietic stem cells.
- the absence of MHC antigen expression at this stage is significant in that the likelihood of rejection of these cells by a genetically disparate host upon in vivo transfer is greatly reduced.
- the lack of Thy-1 _ expression indicates that the yolk sac cells of the invention represent an earlier cell population in ontogeny than the Thy-1 + hematopoietic stem cells found in bone marrow, thus should contain a pluripotent population that is less committed to any 5 specific cell lineages.
- LONG-TERM MAINTENANCE OF YOLK SAC CELLS The yolk sac cells isolated from day 7 embryos were established in culture in the presence of 0 leukemia inhibitory factor (LIF) at 10-100 U/ml without a feeder layer. The cells expanded in number, having a doubling time of about 18 hours. Such cultured cells have been grown in vitro for over 41 passages covering a period of time over nine months in continuous culture. Alternatively, yolk sac cells could.also be grown in stem cell factor with similar results.
- LIF leukemia inhibitory factor
- LIF is capable of suppressing differentiation of the yolk sac cells over an extended period of i vitro growth
- the effect of LIF is incomplete because a small fraction of the cultured cells began to express certain differentiation markers including Thy-1 and MHC-encoded molecules.
- the majority of the long-term cultured cells retained their original cell surface phenotype. Further, such cells continued to be pluripotent as evidenced by their ability to give rise to mature blood cells in vitro and in vivo, infra.
- the cells with the original phenotype in long-term cultures may be obtained by cell sorting or by repeated limiting dilution cloning.
- Fig. 4 is a blood stain of a yolk sac culture grown in the presence of a combination of cytokines and the appearance of various blood cell lineages can be identified.
- the donor cells were identified by antibodies specific for the donor H-2 d haplotype. 0 Double-staining experiments utilizing two antibodies further demonstrated that certain subpopulations of the donor cells expressed CD3, Thy-1, B220 and Ml/70 (FIG. 5) . Therefore, these results indicated that the long-term cultured mouse yolk sac cells were capable 5 of differentiating naturally in vivo into T cells, B cells and macrophages.
- chemotherapeutic drugs are effective, and have been used, as ablative agents for bone-marrow in bone-marrow transplantation procedures (Floersheim and Ruszkiewicz, 1969, Nature
- Busulfan Tet al. , 1987, Blood 70:1382
- Busulfan a drug used to replace whole body irradiation in bone-marrow transplantation procedures.
- Busulfan a drug used to replace whole body irradiation in bone-marrow transplantation procedures.
- Busulfan a drug used to replace whole body irradiation in bone-marrow transplantation procedures.
- doses of Busulfan have been determined which fully ablate the bone-marrow of these mice but do not directly kill them.
- These doses of Busulfan result in the eventual death of the treated mice between 11 and 14 days if they do not receive transplanted bone-marrow.
- This dose is 65 mg of Busulfan/g of body weight administered in a single dose by I. . injection.
- mice While the spleens of control animals were dark, almost black in color, and appeared necrotic, the spleens of transplant recipients displayed a red/pink color and appeared normal and healthy. Further, the survival time of the yolk sac cell-treated mice was extended to between 18 and 20 days.
- a long-term cultured yolk sac cell line was tested for its ability to survive in an allogeneic host.
- 10,000-50,000 BALB/c yolk sac cells after 13-20 passages in vitro were injected in utero in day 8 embryos of C57BL/6 mice.
- the spleens and livers of the neonates were harvested and analyzed for the presence of donor cells.
- FIG. 8 presents the results from two neonates examined and it clearly shows that donor cells were present in both the liver and spleen of the recipient mice in substantial numbers. Therefore, in utero administration of yolk sac cells into MHC-mismatched mice resulted in tissue chimerism, and survival and homing of the cells to the lymphohematopoietic organs. Tissue chimerism was retained when the mouse tissues were examined even one month after birth.
- FIG. 9 demonstrates that a substantial number of blood cells obtained from the sheep were reactive with anti-H-2 d antibody. While there were lower numbers of donors in the peripheral blood of the goat, donor cells were nonetheless detectable. In addition, cells expressing the murine T cell marker Ly-1 were also present from both animals. However, neither animal had cells that were positive for the murine macrophage marker Mac-l, consistent with the fact that macrophages are not normally present in the peripheral blood.
- the tolerized hosts may also accept other solid organs including the heart, liver and kidney from xenogeneic donors sharing the same haplotype of the original donors.
- the expression of a T cell marker indicates normal differentiation and maturation in vivo, and the absence of macrophages in the peripheral blood suggests the appropriate homing of the right cell lineages in the host upon intravenous administration of yolk sac cells.
- EXAMPLE IN VIVO TRANSFORMATION OF YOLK SAC CELLS
- both untransformed yolk sac cells and a retroviral vector containing the exogenous gene of interest are injected into the target animal.
- the exogenous gene used is the growth hormone gene (bGH) .
- Yolk sac cells harvested from day 8 C57/SJL mouse embryos are cultured on an STO feeder layer system until approximately 20 x 10 6 cells per culture flask (150 cm) were generated. Cells were passed to new flasks when the cell density became greater than 80%. All experiments were performed with cells at passage 10 or greater.
- mice were injected I.P. with yolk sac cells (2-4 x 10 6 ) at 3 to 5 days of age. Two months (positive results have been observed with infections as early as two weeks following yolk sac injection) after I.P. injection of yolk sac cells, animals received lxlO 6 viral particles of a replication deficient retroviral vector produced from the Moloney murine Leukemia Virus based Mulligan ⁇ 2 packaging cell line after transformation with the plasmid pLJPCKbGH by I.V. injection into the tail vein. Of 145 animals treated by this procedure, 112 were positive for bGH in the serum by ELISA assay. The following is a breakdown of the positive bGH levels of these test animals:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pregnancy & Childbirth (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
La présente invention concerne des cellules souches de sac vitellin, en particulier la caractérisation, la culture et les utilisations de cellules souches de sac vitellin en vue de la reconstitution et de la thérapie hématopoïétiques. Des cellules souches de sac vitellin isolées du sac vitellin embryonnaire précoce avant la formation d'îlots sanguins présentent une morphologie homogène et un phénotype de surface cellulaire primitif sans l'expression de marqueurs de leucocytes matures et des antigènes codés par le complexe d'histocompatibilité majeure. Les cellules peuvent être cultivées et multipliées à long terme sans altération de leur pluripotence. Par conséquent, lesdites cellules souches de sac vitellin peuvent avoir une large gamme d'applications qui comprend, entre autres, la reconstitution d'un système hématopoïétique humain déficient ou détruit et la construction de modèles animaux de petite et de grande taille pour la production de cellules sanguines humaines et d'anticorps humains et pour le test de maladies humaines, de la fonction immunitaire, de vaccins, de médicaments et de l'immunothérapie.The present invention relates to yolk sac stem cells, in particular the characterization, culture and uses of yolk sac stem cells for hematopoietic reconstitution and therapy. Yolk sac stem cells isolated from the embryonic yolk sac early before blood islets display a homogeneous morphology and a primitive cell surface phenotype without the expression of mature leukocyte markers and antigens encoded by the major histocompatibility complex . The cells can be cultivated and multiplied in the long term without altering their pluripotency. Therefore, said yolk sac stem cells can have a wide range of applications which includes, inter alia, the reconstruction of a defective or destroyed human hematopoietic system and the construction of small and large animal models for the production of human blood cells and human antibodies and for testing human diseases, immune function, vaccines, drugs and immunotherapy.
Description
YOLK SAC STEM CELLS
1. INTRODUCTION The present invention is directed to yolk sac stem cells. In particular, it relates to the characterization, culturing, and uses of yolk sac stem cells for hematopoietic reconstitution and therapy. Yolk sac stem cells isolated from the early embryonic yolk sac prior to blood island formation exhibit a homogeneous morphology and a primitive cell surface phenotype without the expression of mature leukocyte markers and major histocompatibility complex encoded antigens. The cells can be cultured and expanded long-term without alteration of their pluripotency. Therefore, yolk sac stem cells may have a wide range of applications including but not limited to the reconstitution of a destroyed or deficient human hematopoietic system, and the construction of large and small animal models for the production of human blood cells, human antibodies, and testing of human diseases, immune function, vaccines, drugs and immunotherapy.
2. BACKGROUND OF THE INVENTION A multipotential stem cell population is capable of giving rise to blood cells of diverse morphology and function (Golde, 1991, Scientific American, December:86) . Since blood cell formation is first detectable in the embryonic yolk sac early in embryogenesis, it has been hypothesized that pluripotent hematopoietic stem cells may be present within the yolk sac, but the characteristics of such cells are still poorly understood and such cells have not heretofore been identified (Moore and Metcalf, 1970, 18:279). During fetal development, the stem
cells migrate to the fetal liver where they reside temporarily, and eventually move to give rise to the bone marrow which is the permanent site of blood cell formation in the adult. Studies on the development of blood cells have led to the identification of a variety of important growth and differentiation factors that regulate hematopoiesis. Further, tissue typing technology has ushered in dramatic advances in the use of hematopoietic stem cells as a form of therapy in patients with deficient or abnormal hematopoiesis.
2.1. HEMATOPOIETIC STEM CELLS A pluripotent stem cell is believed to be capable of self-renewal and differentiation into blood cells of various lineages including lymphocytes, granulocytes, acrophages/monocytes, erythrocytes and megakaryocytes (Ikuta et al., 1992, Ann. Rev. Immunol. 10:759) . The mechanism by which a stem cell commits to a specific cell lineage has not been fully elucidated. The mechanisms involved in stem cell replication without differentiation are also unknown. However, it is clear that such events must, in part, be influenced by a variety of growth and differentiation factors that specifically regulate hematopoiesis. Other factors which are not yet identified may also be involved (Metcalf, 1989, Nature 339:27). The commonly known hematopoietic factors include erythropoietin (EPO) , granulocyte/macrophage colony stimulating factor (G/M-CSF) , granulocyte colony-stimulating factor (G-CSF) , macrophage colony-stimulating (M-CSF) , interleukin 1-12 (IL-1 to IL-12) , and stem cell factor (SCF) .
An understanding of hematopoiesis is critical to the therapy of hematopoietic disorders.
Neoplastic transformation, immunodeficiency, genetic abnormalities, and even viral infections all can affect blood cells of different lineages and at different stages of development. For example, basic knowledge of blood cell development has contributed to the success of bone marrow transplantation in the treatment of certain forms of hematopoietic malignancies and anemias.
Conventional therapy utilizes whole bone marrow harvested from the iliac crest but this approach has certain limitations. Bone marrow stem cells are present at extremely low concentrations, and they may not be at the earliest stage of differentiation. An impediment in bone marrow transplantation is the need for matching the major histocompatibility complex (MHC) between donors and recipients through HLA tissue typing techniques. Matching at major loci within the MHC class I and class II genes is critical to the prevention of rejection responses by the recipient against the engrafted cells, and more importantly, donor cells may also mediate an immunological reaction to the host tissues referred to as graft versus host disease. In order to facilitate graft acceptance by the host, immunosuppressive agents often have been employed, which render the patients susceptible to a wide range of opportunistic infections.
Hollands examined the in vivo potential of embryonic cells, and found that day 7 embryonic mouse cells could colonize the hematopoietic system of normal non-irradiated allogeneic mice (Hollands, 1988, British J. Haematol. 69:437). However, it was not clear which embryonic cell population actually contributed to this result, as total embryonic cells were used for in vivo transfer. In a study on the
effects of in utero cell transfer, day 9 yolk sac cells were injected into syngeneic fetuses which differed from the donor cells only at the 0-globin locus (Toles et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:7456) . The donor cells were shown to induce hematopoiesis. Both of these n vivo studies utilized freshly isolated cells from mouse embryos, and there was no suggestion that long-term cultured and expanded embryonic yolk sac cells could retain their pluripotency. Such methods involved diffusion chambers embedded within the species of origin of the yolk sac tissue (Symann et al. , Exp. Hemat. 6:749, 1978) or methods that led to in vitro malignant transformation of the yolk sac cells. For example, long-term yolk sac cell lines were established from day 10-13 mouse embryos, and they were shown to give rise to tumor cells at high frequency (Globerson et al., 1987, Differentiation 36:185). Therefore, the potential of tumor formation renders such long-term cultured cells undesirable for use in reconstitution therap .
2.2. MAJOR HISTOCOMPATIBILITY COMPLEX The MHC is a highly polymorphic complex of genes (Bach and Sachs, 1987, New Eng. J. Med. 317:489). It was first discovered by its close association with the phenomenon of transplantation rejection of tissue grafts. Subsequent studies conclusively demonstrated that antigens encoded by MHC class I genes are the major targets of transplantation rejection responses. Such antigens are expressed by- all somatic cells.
MHC class II genes encode molecules on a limited array of cells, most of which are related to
— o —
the hematopoietic system. They can also elicit reactions by allogeneic immune cells.
Studies on the expression of MHC antigens by embryonic yolk sac cells yielded inconsistent results. Billington and Jenkinson (Transplantation 18:286,
1974) , working with cells of the yolk sac of 10-14 day mouse embryos, found that these cells expressed both H-2 and non-H2 (murine major and minor histocompatibility) antigens. The work of Patthey & Edidin (Transplantation 15:211, 1973), cited by
Billington and Jenkinson, reported that H-2 antigens first appeared on day 7 embryos which could provoke a strong immune reaction, but the latter suggested that these antigens did not make an appearance in utero until day 9 or later. See THE EARLY DEVELOPMENT OF MAMMALS 219 (Balls and Wild, eds., Cambridge U.:1975). Heyner reported that H-2 antigens were detectable in day 7 mouse embryos (Heyner, 1973, Transplantation 16:675). Further, mouse yolk sac cells obtained at day 9 of gestation were shown to be capable of generating a graft-versus-host response in vitro (Hofman and Globerson, 1973, Eur. J. Immunol. 3:179). However, Parr et al. demonstrated that H-2 antigens were absent on the apical or the laterobasal membrane of the mouse yolk sac endoderm even at day 20 of pregnancy (Parr et al., 1980, J. Exp. Med. 152:945). Thus, no consensus has been established in regard to the antigenicity of yolk sac cells.
3. SUMMARY OF THE INVENTION
The present invention relates to yolk sac stem cells, a method of isolating and culturing yolk sac stem cells, and a method of using the cultured yolk sac cells for reconstituting an allogeneic or xenogeneic hematopoietic system.
The invention is based, in part, on Applicants1 discovery that the murine yolk sac, isolated from mouse embryos prior to visible blood island formation, contains a homogeneous population of cells that are CD34+, Thy-1~, MHC class I- and class II-. Such cells can be expanded in number by long-term in vitro culture with minimal differentiation, and can give rise to mature blood cells of diverse lineages when subsequently treated with the appropriate hematopoietic growth and differentiation factors. Further, the long-term cultured cells also can mature into functionally competent blood cells in vivo, capable of mediating antigen-specific immune responses, repopulating lympho-hematopoietic organs, and prolonging survival of animals with a destroyed hematopoietic system. The yolk sac cells of the invention can be successfully transplanted into allogeneic fetuses in utero and into non-immunosuppressed xenogeneic hosts and since these cells do not induce graft-versus-host and host-versus-graft reactions, transplantation will result in tissue chimerism.
The invention is described by way of examples in which murine yolk sac cells are isolated, and their cell surface phenotype is characterized. The homogeneous population of yolk sac cells is expanded in long-term culture, and shown to retain pluripotency in vitro and in vivo. A wide variety of uses for the yolk sac cells are encompassed by the invention described herein.
4. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1. A schematic drawing of the appearance of mouse embryos around day 7 and day 8.5 of gestation.
FIG. 2. Murine yolk sac cells from a day 7 embryo are more homogeneous in appearance than cells from a day 8.5 embryo by flow cytometry analysis.
FIG. 3. Murine yolk sac cells from a day 7 embryo express CD34 but not Thy-1, MHC class I and class II antigens.
FIG. 4. Cultured yolk sac cells can differentiate into mature blood cells in vitro, including (4A) monocytes, (4B) megakaryocytes, (4C) erythrocytes, and (4D) lymphocytes.
FIG. 5. Yolk sac cells recovered from recipient mouse spleens following n vivo transfer demonstrate the expression of mature leukocyte antigens by donor cells.
FIG. 6. Hemagglutination of red blood cells coated with antigens (FIG. 6A, lipopolysaccharide, and FIG. 6B, human serum albumin) by sera of immunodeficient mice treated with yolk sac cells, demonstrating restoration of immune function by yolk sac cells in vivo.
FIG. 7. Cultured yolk sac cells repopulate the spleens of chemically-ablated mice and give rise to colony-forming units in vivo; (7A) A comparison between a chemo-ablated mouse spleen and a fully repopulated spleen; (7B) A repopulated spleen at day 7 post-yolk sac treatment; (7C) A populated spleen at day 14 post yolk-sac treatment.
FIG..8. In utero injection of yolk sac cells into allogenic mice leads to tissue chimerism in new born mice.
FIG. 9. Survival and differentiation of long-term cultured murine yolk sac cells in a sheep and a goat which had received multiple high doses of yolk sac cells.
5. DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to yolk sac stem cells, to methods of isolating and culturing the yolk sac stem cells, and to methods of using the yolk sac stem cells. Although the specific procedures and methods described herein are exemplified using murine yolk sac cells, they are merely illustrative for the practice of the invention. Analogous procedures and techniques are equally applicable to all mammalian species, including human subjects. Therefore, human yolk sac stem cells may be isolated from the embryonic yolk sac prior to blood island formation. The cells having the phenotype of CD34+, Thy-1—, and MHC class I- and II- may be cultured under the same conditions described herein, infra.
Mammalian development may be divided into three distinct stages: the zy ote, from fertilization to cleavage; the embryo, from cleavage to the formation of all somites; and the fetus, from the formation of the last somite until birth. This invention takes advantage of the unique properties of embryonic yolk sac cells after their course of development is determined, but before they have lost either immuno-incompetency or the ability to proliferate rapidly.
It is known that when completely undifferentiated cells of the blastula or morula are transplanted into a developed animal, they produce tumors. These totipotent, tumorigenic cells are of no value for in vivo reconstitution therapy. However, in accordance with the invention, it is advantageous to transplant cells which have reached a stage of specialization at which they have become committed to a particular sequence of development, or lineage. Such cells may be used alone or to deliver genetic material, or its expression products, into a particular tissue of the body, including blood cells. The cells can be transplanted into a host before or after transformation with an exogenous gene of interest, and allowed to develop into the target tissue.
While it is necessary to use cells which have matured to the point of losing totipotency, fully mature cells will be rejected by a histoincompatible host. Consequently, it is desirable to use cells which have just lost totipotency, but still retain pluripotency for a particular tissue type. Such cells also may retain the ability to colonize, thus facilitating their delivery to the target tissue. Stem cells of the embryonic yolk sac offer particular advantages for hematopoietic reconstitution. Unlike the cells of the embryo, the cells of the yolk sac develop into only a small number of different tissues. Among those tissues is the hematopoietic system, which includes the red and white blood cells, and the tissue of the veins, arteries and capillaries. Thus, by day 8 in the development of the mouse embryo, mesodermal cells in the yolk sac begin to form blood islands. The cells of the blood islands differentiate, the peripheral cells becoming the
endothelium of the future blood vessels, and the central cells becoming first mesenchymal cells and then the red and white blood cells. The blood islands establish communications to form a circulatory network, which is extended into the embryo proper.
The yolk sac cells of the subject invention do not express MHC antigens, and can mature in allogeneic and xenogeneic hosts, demonstrating their ability to escape immune rejection. By contrast, research with bone marrow cells has depended on the use of immunocompromised hosts. The culture methods described herein maintain the yolk sac in their undifferentiated state, and are applicable to mass culture of yolk sac cells, providing donor cells for large numbers of recipients.
5.1. ISOLATION OF YOLK SAC CELLS The embryonic yolk sac is the first identifiable site of blood cell formation in ontogeny. The yolk sac cells travel to the fetal liver during embryogenesis and eventually migrate to the bone marrow where they reside and differentiate into mature blood cells throughout the entire adult life.
The embryonic development of the mammalian yolk sac is rapid and occurs within a narrow time frame. The murine yolk sac is fully formed by day 7 of gestation, and the formation of blood is detectable in the mesenchyme of the body stalk and in neighboring areas of the yolk sac. Shortly thereafter, masses of mesenchymal cells round up and become aggregated to form blood islands. By day 8.5, extensive blood island formation in the murine yolk sac is readily visible microscopically. At this stage, embryonic development has reached a level where fetal liver is formed and yolk sac cells begin to migrate to the
- 1 ,1 „ -
fetal liver. Upon the departure of the yolk sac stem cells, the yolk sac begins to atrophy. Similar events also occur in embryonic development of other species, but the timing of developmental events varies between different species. In humans, the yolk sac is formed by day 10 of gestation, and blood island formation occurs shortly thereafter. Thus, human yolk sac cells isolated at day 10 may be comparable to the murine cells at day 7. Since the yolk sac is where blood cell formation is first established in development and the yolk sac cells eventually reach the bone marrow to become the bone marrow hematopoietic cells, it is reasoned that the yolk sac represents the earliest site for the generation of primordial hematopoietic cell precursors. The cells have committed to the hematopoietic differentiative pathway so that they are no longer totipotent. However, the yolk sac cells are still pluripotent, since they have not yet committed to a particular blood cell lineage as seen by their ability to make cells of lymphoid, myeloid, and erythroid lineages. Hence, yolk sac cells may be the ideal cell population for use in reconstitution therapy including, but not limited to, bone marrow transplantation. In addition, the primitive nature of these cells, as evidenced by the absence of cell surface expression of various mature markers and MHC transplantation rejection antigens, may render these cells uniquely capable of being used as a universal donor cell population in allogeneic and even xenogeneic hosts.
The isolation of the embryonic yolk sac may be achieved using a variety of surgical methods. Traditionally, the yolk sac of a mouse embryo is disaggregated by the use of enzymatic digestion and
mechanical separation upon surgical removal. A gentler method of detaching the cells from the yolk sac membrane and separating them from each other is described in Section 6.2.1. in which a yolk sac is immersed in an EDTA solution which causes the cells to segregate and form a single cell suspension. This method minimizes cell lysis due to physical force and cell surface protein alteration due to enzymatic treatment. Since the establishment of blood islands in the yolk sac marks the beginning of cellular differentiation and blood cell formation, it is preferable that yolk sac cells be isolated prior to extensive blood island formation. Large numbers of highly homogeneous yolk sac cells of day 7 murine embryos (or similar stage human yolk sac cells) , can be isolated using the method described herein, and cells obtained at this stage should in principle contain the least committed and least differentiated pluripotent stem cells suitable for long-term in vitro culture, for use in immediate in vivo therapy or as carriers of specific exogenous genes for use in gene therapy.
For long-term maintenance of the yolk sac cells, the cells are grown in medium containing a relatively high concentration of serum supplement, between 15-20%. Various cytokines may be added to suppress differentiation of the stem cells, including but not limited to, leukemia inhibitory factor (LIF) or stem cell factor/the c-kit ligand (SCF) or SCF in combination with other cytokines such as IL-3. Such factors accelerate the multiplication of cultured cells, while inhibiting cellular differentiation in vitro. The examples presented in Section 6, infra, were all performed using yolk sac cells grown in the
— 13 —
presence of 10-100 U/ml of LIF. However, higher LIF concentrations may be used to achieve stronger suppression of differentiation. The growth of cells using SCF could produce similar results. Alternatively, a number of other known hematopoietic factors such as IL-3, CSF's and EPO also may be used in combination depending on the need to select for a particular cell type. For example, the combined use of IL-3 and EPO may assist in driving cultured yolk sac cells towards the erythroid pathway. The maintenance of cells at the appropriate temperature, C02 concentration, humidity level and the frequency of changing the culture media are within the ordinary skill of the art.
5.2. CHARACTERIZATION OF YOLK SAC CELLS
As shown by the examples described herein, yolk sac cells obtained from mouse embryos prior to blood island formation are more homogeneous in appearance than cells obtained at a later stage.
Freshly isolated yolk sac cells from day 7 and day 8.5 murine embryos were compared by light scattering using flow cytometry analysis, see Section 6.2.1., infra. It is apparent that yolk sac cells of day 7 mouse embryos are extremely uniform with respect to both cell size and cell shape. By day 8.5, distinct populations of cells are clearly visible, suggesting that the earlier stage yolk sac cells may be clonally derived and the difference of 1 day in development may be critical to the nature of the yolk sac cells.
Another indication of the primitive nature of the early yolk sac cells is their cell surface phenotype in regard to the expression of various lineage-specific blood cell markers. This form of analysis may be most conveniently carried out by the
use of a panel of marker-specific monoclonal antibodies. When the day 7 yolk sac cells were reacted with antibodies, the results showed that they lacked expression of all mature blood cell markers. In addition, such cells did not express MHC-encoded products which are the major targets of transplantation rejection responses. Thus, yolk sac stem cells can be characterized as CD34+, Thy-1—, MHC class I- and MHC class II-. Similarly, human yolk sac stem cells obtained from day 10 embryos should display an identical cell surface phenotype.
The CD34 and Thy-1 markers previously have been demonstrated to be associated with bone marrow hematopoietic stem cells (Spangrude et al. , 1988, Science 241:58) . While CD34 expression declines as stem cells differentiate and mature, the presence of Thy-1 is retained and its density increased in certain mature blood cells, particularly T-lymphocytes. The finding that yolk sac stem cells are positive for CD34 expression is consistent with these cells being stem cells. However, the absence of Thy-1 expression suggests that yolk sac cells may represent an earlier cell population than the bone marrow stem cells which express low levels of Thy-1 in the bone marrow microenvironment. In fact, when yolk sac cells are cultured in vitro, a small percentage of the cells escape the effect of LIF and begin to express Thy-1, further suggesting that Thy-1 expression is a later event of stem cell development. MHC-encoded class I and class II molecules are involved in immune regulation between T, B, and antigen presenting cells. These highly polymorphic molecules also serve as targets in major transplantation rejection responses between genetically mismatched individuals. Therefore, HLA
— o —
tissue typing is currently a routine clinical procedure in ensuring graft acceptance in human transplant patients by matching the donors and recipients at the major MHC genetic loci. The absence of MHC antigens on the yolk sac cell surface strongly suggests the possibility of using such cells as universal donors in hematopoietic reconstitution therapy, alleviating the need of tissue typing and the restrictive use of only MHC-matched tissues as donor cells. The development of adoptively transferred yolk sac cells in the environment of the host may lead to specific tolerance between the host and donor cells for each other, causing a diminution of the potential for inducing graft-versus-host and host-versus-graft reactions.
The above-described yolk sac phenotype is seen with the vast majority of cells isolated from day 7 murine embryos. Therefore, early isolation of yolk sac cells provides for a highly homogeneous and enriched population of stem cells. This is in contradistinction to the purification procedure needed for murine bone marrow hematopoietic stem cells which are of CD34+ and Thy-1+ phenotype. Such cells must be isolated and enriched by a series of selection steps, as they constitute only less than 0.1% of the total cells in the bone marrow (Spangrude et al., 1991, Blood 78:1395). On the other hand, yolk sac stem cells can be obtained in an essentially homogeneous state without requiring additional purification, and such cells retain their phenotype and functional activity during long-term in vitro growth.
5.3. FUNCTIONAL ACTIVITIES OF YOLK SAC CELLS
The pluripotency of yolk sac stem cells to differentiate and mature into functionally competent
— lo "*
blood, cells of various hematopoietic lineages was tested by a number of in vitro and in vivo methods described herein. The presence of a pluripotent population in long-term cultured yolk sac cells was first demonstrated as follows. After 10 passages of in vitro growth, yolk sac cells were washed from LIF and exposed to a combination of cytokines including IL-3, CSF's, and EPO at previously determined optimal concentrations for an additional three weeks in culture. At the end of the period, the stimulated yolk sac cells were prepared as blood smears and stained with hematoxylin. The result of this analysis reveals the appearance of blood cells that can be identified as erythrocytes, granulocytes, megakaryocytes, and lymphocytes.
A similar study also was carried out in vivo by recovering donor cells four weeks after in vivo injection into allogeneic SCID mice. The yolk sac cells used in this study had been expanded in culture for over 40 passages. Double-staining of the spleen, bone marrow, and thymus cells of the SCID mice was performed using antibodies specific for the donor cell haplotype of H-2d and antibodies against mature blood cell markers such as B220 for B cells, CD3 and Thy-1 for T cells, and Mac-1 for macrophages. The results of this in vivo study confirm the in vitro study that long-term cultured yolk sac cells are capable of giving rise to mature T cells, B cells and macrophages/monocytes. In addition to morphologic evidence of blood cell maturation from yolk sac cells, the adoptively transferred yolk sac cells were tested for functional activities in the form of specific antibody production. One month after receiving an infusion of yolk sac cells, the mice were immunized with either
lipopolysaccharide (LPS) or human serum albumin (HSA) . Sera of mice were diluted serially, reacted with the two antigens, and compared with normal mouse sera as controls. LPS is a T cell-independent antigen which activates polyclonal B cells directly. The high titer of LPS specific antibodies in the sera of yolk sac cell-bearing beige nude xid mice after LPS immunization indicates the presence of functionally competent antibody producing cells, i.e., B lymphocytes and plasma cells. Additionally, HSA, which is a T cell dependent antigen, elicited a weaker yet detectable specific antibody production in mice. Since the anti-HSA antibody response requires T cell help which, in turn, is first activated by antigen- presenting cells such as macrophages, this result provides evidence for the presence of mature and functional T cells, B cells, and macrophages which co¬ operate and interact in the generation of antibodies. As a corollary, this also suggests that other T cell and macrophage-mediated functions such as cytotoxicity, lymphokine and cytokine secretion, phagocytosis, antigen processing and presentation may all develop from the transferred yolk sac stem cells. The in vivo transfer of yolk sac cells also repopulated the spleens of mice whose hematopoietic system had been previously destroyed by chemical ablation or lethal doses of irradiation. This resembles situations in which a patient's lymphohematopoietic system is deficient due to a genetic disorder or an acquired viral infection, or a patient's system is intentionally destroyed by chemotherapy or radiotherapy in order to eradicate tumor cells in the bone marrow. The administration of yolk sac cells induced colony forming units-spleen (CFU-S) in lethally irradiated or chemo-ablated mice
whose, spleens, otherwise, frequently exhibited a necrotic appearance. On the other hand, expansion of the yolk sac cells over a period of time in vivo supported repopulation and restoration of spleens completely normal in appearance. Further, the yolk sac cell-treated mice experienced a prolongation of survival time when compared with the untreated control group. Therefore, long-term cultured yolk sac cells may be useful in a variety of settings in which bone marrow reconstitution can be applied as an effective means of therapy.
Transplantation of murine yolk sac cells into allogeneic fetuses in utero and xenogeneic new born animals did not induce graft rejection reactions. The yolk sac cells persisted in vivo and established hematopoietic chi erism in the spleen, liver, and peripheral blood of the host. Thus, yolk sac cells may be useful as universal donor cells in various mammalian species, including humans.
5.4. USES OF YOLK SAC STEM CELLS The absence of MHC antigen expression by yolk sac stem cells provides for a source of donor cells for in vivo transplantation and reconstitution therapy. The cells may be used immediately after isolation from the yolk sac or after long-term expansion in vitro. in order to procure larger numbers for more effective doses. Introduction of exogenous genes into the yolk sac cells may be achieved by conventional methods during n vitro culture and/or in vivo gene therapy. Long-term cultured cells may be used as a mixed population or progenitors can be pre-selected based on the primitive phenotype of CD34+, Thy-1, MHC class I- and class II-, or by limiting dilution cloning, prior to in vivo use.
5.4.1. HUMAN YOLK SAC CELLS IN MICE Human yolk sac cells may be obtained, grown in vitro and transferred into immunodeficient or immunocompromised mice. Such mice contain a human hematopoietic system and may be used for the study of human blood cell development in vivo, the " identification of novel hematopoietic growth and differentiation factors, and testing for cytotoxic and/or inhibitory compounds that affect various stages of blood cell formation as well as anti-cancer drugs. Such a chimeric mouse referred to as Hu atoMouse™ herein would be superior to the conventional SCID/Hu mouse model in which mice are reconstituted with human bone marrow stem cells because HumatoMouse™ would permit studies in the delineation of the earliest events in hematopoiesis. Furthermore, yolk sac cells may be implanted in utero into normal mouse fetuses for engraftment of human blood cells in a normal mouse environment. Such yolk sac cells may be transfected with a drug-resistance gene so as to allow subsequent selective ablation of only the host cells using the corresponding drug.
It has been observed that SCID mice are not totally immunodeficient and that a small amount of restoration of immune function is correlated with the age of the mice. SCID mice possess detectable natural killer cell and macrophage activities. A small percentage of mice even re-acquire T and B cell function as they mature. Thus, conventional SCID mice may not be the most appropriate hosts for the construction of the HumatoMouse™ as their immune function may interfere with the analysis of the donor yolk sac cells. The steel mice possess a mutation at the steel locus which encodes SCF, a ligand for the proto-oncogene c-kit cell surface receptor. Mouse
fetuses that are homozygous for this mutation live only to about day 15 of gestation before they are aborted due to the absence of a hematopoietic system and blood cell formation. Hence, human yolk sac cells may be injected into the developing homozygous fetuses in utero prior to abortion, e.g., at day 8, to reconstitute their hematopoietic function. The resulting neonates should have a fully humanized system with no contribution by the host as they would not normally have lived to birth.
Studies described herein demonstrate that cultured yolk sac cells can develop into mature blood cells jLn vivo, suggesting that the cells secrete the necessary growth and differentiation factors for supporting their own development. A further improvement of the Humatomouse™ model includes the introduction of human growth and differentiation factor genes in the mice. In the event that certain of the critical cytokines for human blood cell formation are species-specific, such as SCF, and mouse molecules do not act effectively to promote growth and differentiation of human cells, transgenic SCID or steel mice may be constructed to result in endogenous production of human cytokines of interest such as IL-3, CSF's, and SCF. Alternatively, human yolk sac cells may be transfected with murine receptor genes. The subsequent transfer of human yolk sac cells to these mice should give rise to a more complete and efficient human hematopoietic system in mice.
5.4.2. TRANSPLANTATION USING YOLK SAC CELLS The repeated transfer of high doses of long-term cultured mouse yolk sac cells into a foreign species, i.e. sheep, has shown that the cells persist in vivo, differentiate into mature lymphocytes, and do
not mediate graft versus host disease. Although the mature donor mouse cells eventually express MHC antigens in vivo, the donor cells are present in high quantities in the peripheral blood of the xenogeneic host. The absence of graft rejection (host versus graft) and graft versus host reactions may be attributed to the primitive nature of the yolk sac cells, particularly the lack of MHC antigen expression, allowing the cells and the host immune system to "learn" each other as self prior to MHC expression and thus, induce a state of specific tolerance.
Xenogeneic transplants of solid organs have been carried out in humans in situations where there is a shortage of HLA- atched organs. With respect to xenogeneic transplant of primitive hematopoietic stem cells, yolk sac cells may be used to reconstitute the hematopoietic system of any mammalian species, for example, in a human patient with HIV infection, since non-human T cells cannot be infected by human HIV, this approach may serve as a means of limiting HIV infection in humans. Yolk sac cells may also be transfected with genes which are designed to disrupt HIV gene sequences involved in HIV replication prior to in vivo administration. Such exogenously introduced genes may encode anti-sense RNA or ribozyme molecules that specifically interfere with HIV replication. Further, the induction of tolerance by the transfer of xenogeneic yolk sac cells may allow subsequent transplantation of solid organs, including but not limited to heart, liver and kidney from donor animals sharing the same genetic makeup of the yolk sac donors. This raises the possibility of using MHC-mismatched yolk sac cells not only for reconstitution purposes, but also as first step
tolerogens for inducing specific tolerance in a recipient for subsequent organ transplants.
In addition, this form of yolk sac cell transplantation may be applied in situations where a genetic defect has been detected in a fetus. Human or other mammalian yolk sac cells carrying a normal wild type gene or an exogenously introduced gene may be injected into the developing fetus in a routine procedure similar to that of amniocentesis in utero. The genetic disorders for which this approach may be applicable include, but are not limited to, sickle cell anemia, thalassemia, and adenosine deaminase deficiency. Alternatively, yolk sac cells may be used in settings where a pregnant mother is diagnosed to carry HIV, and reconstitution of the fetus with yolk sac cells may prevent viral infection of the fetus. The ability of yolk sac cells to grow in xenogeneic animals with no irradiation or chemical treatment allows for large scale production of human hematopoietic cells and their secreted factors in vivo. Human yolk sac cells may be injected in a large farm animal, the blood collected, and large quantities of human proteins or cells such as red blood cells, lymphocytes, granulocytes, platelets, monoclonal antibodies and cytokines purified for clinical use.
5.5. BONE MARROW REPLACEMENT THERAPY IN HUMANS A protocol for the replacement of bone marrow cells in human patients requiring bone marrow transplantation may be devised using cultured human or xenogeneic yolk sac cells. Yolk sac cells obtained from human yolk sac at day 10 of gestation may be isolated using the procedures described herein, expanded in culture, and cryogenically preserved as donor cells for the transplant.
Ablation of recipient patient bone marrow cells may not be required, but if it is used, it can be accomplished by standard total body irradiation (Kim, et al., Radiology, 122:523, 1977) or by chemotherapy with a variety of commonly used compounds including, but not limited to Busulfan (Tutschka, et al., Blood, 70:1382-1388, 1987), following the conventional methods. Yolk sac cells can be introduced into the recipient, using similar methods for bone marrow cells. Prior to in vivo transfer, yolk sac cells may be transformed with a drug- resistance gene, such as the methotrexate resistance gene. This allows the subsequent use of high doses of the corresponding chemotherapeutic drug to eradicate the less resistant host cells in a patient, without damage to the transferred yolk sac cells. Post¬ operative care would be the same as with transplantation using bone marrow cells from a donor. High doses of yolk sac cells obtained from allogeneic or xenogeneic sources may be continuously infused into a bone marrow transplant recipient in the absence of prior chemotherapy or radiotherapy. This presents a novel approach to bone marrow transplantation without immunosuppressing the recipient.
5.6. IDENTIFICATION OF NEW
MARKERS ON YOLK SAC CELLS
Murine yolk sac cells express CD34 but none of the other known leukocyte markers. It is possible that yolk sac cells express other early markers which have not yet been identified. If so, previous failure in identifying these unique molecules might be due to their decreased expression in more mature cells or even stem cells after migration to other sites out of the yolk sac. Therefore, yolk sac cells may be used
to generate antibodies against their cell surface antigens in order to identify and characterize such unknown markers.
Also within the scope of the invention is the production of polyclonal and monoclonal antibodies which recognize novel antigenic markers expressed by yolk sac cells. Various procedures known in the art may be used for the production of antibodies to yolk sac cells. For the production of antibodies, various host animals can be immunized by injection with viable yolk sac cells, fixed cells or membrane preparations, including, but not limited to, those of rabbits, hamsters, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to
Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corvnebacterium parvum.
Monoclonal antibodies to novel antigens on yolk sac cells may be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique originally described by Kohler and Milstein (1975, Nature 256, 495-497) , the more recent human B- cell hybridoma technique (Kosbor et al., 1983,
Immunology Today 4:72; Cote et al. , 1983, Proc. Natl. Acad. Sci. 80:2026-2030) and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Techniques developed for the production of "chimeric
antibodies" by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule can be used (e.g.. Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature 314:452-454). In addition, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce single chain antibodies.
Syngeneic, allogeneic, and xenogeneic hosts may be immunized with yolk sac cells which can be prepared in viable form, or in fixed form, or as extracted membrane fragments. Monoclonal antibodies can be screened differentially by selective binding to yolk sac cells, but not to mature macrophages, granulocytes, T, and B cells.
Antibody fragments which contain the binding site of the molecule may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragments.
6. EXAMPLE: GENERATION OF YOLK SAC STEM CELLS FOR IN VIVO HEMATOPOIETIC RECONSTITUTION
6.1. MATERIALS AND METHODS
6.1.1. ANIMALS BALB/c, C57BL/6, beige nude X-linked immunodeficient (BNX) , and C3H/SCID mice were purchased from Jackson Laboratories (Bar Harbor, ME)
— ^o -•
and kept in the animal facility of Edison Animal Biotechnology Center.
6.1.2. ISOLATION OF THE YOLK SAC On day 7 of gestation (day of plug was counted as day 0, female mice were sacrificed by cervical dislocation, and uteri containing embryos were placed in petri dishes with Dulbecco's Phosphate Buffered Saline (PBS) plus penicillin and streptomycin antibiotics (final concentration :1000 units potassium penicillin G and 1000 μg streptomycin sulfate/ml) .
Under a laminar air-flow bench ,each uterine segment containing an embryo was aseptically removed by dissection with the aid of a dissenting microscope. Each embryo surrounded by decidua capsularis was transferred to another petri dish containing PBS plus penicillin-streptomycin. The decidua capsularis was opened with watchmaker's forceps and each embryo transferred into an individual petri dish where yolk sac tissue was excised from the amnion, placenta, embryo, and Reichert's membrane in 0.02% EDTA in PBS at 4°C for 15-30 minutes. The yolk sac cells in single cell suspension were then washed in PBS before culturing.
6.1.3. CULTURE CONDITIONS Disaggregated yolk sac cells were grown in alpha medium (Sigma) supplemented with 18% heat-inactivated fetal calf serum, 0.2 Mm 3-mercaptoethanol, 50 μg/ml of gentamicin and 10% LIF conditioned medium (medium of a LIF-producing cell line, Cho LIFD at 100-1000 u/ml) . Cells were grown without feeder layers on collagen or gelatin coated dishes and incubated at 37°C in 5% C02 in air. Media were changed every other day.
6.1.4. FLOW CYTOMETRY ANALYSIS 106 yolk sac cells were washed twice in cold PBS containing 0.1 BSA and sodium azide. The cell pellets were suspended in the same buffer containing the test antibodies at 4°C for 30 minutes. Cells were then washed in cold PBS twice and analyzed by flow cytometry. Antibodies specific for Thy-1, Ly-1, Ly-2, Mac-l, MHC class I and class II were purchased from Boehringer Mannheim. Anti-Ml/70, anti-H2d and anti-H2b antibodies were purchased from Pharmingen (San Diego, CA) . Anti-CD34 was used as hybridoma supernatant.
6.1.5. INDUCTION OF YOLK SAC DIFFERENTIATION BALB/c yolk sac cells were grown to approximately 50% confluency in medium containing LIF. The cells were harvested, washed and medium containing growth factors was added. Growth factors used were: LIF (100-1000 U/ml) , SCF (50 U/ml) , EPO (1-25 U/ml) , IL-2 (10-200 U/ml) , and IL-3 (10-200 U/ml) in various combinations. The medium was changed every 2 days until confluency was reached, at which time the yolk sac cells were passed 1:4 into new gelatinized 35 mm culture dishes. At day 5, and 21, cells were prepared for blood staining. Day 0, 5, and 21 cells were analyzed by flow cytometry for the appearance of differentiated blood cells.
6.1.6. HEMAGGLUTINATION ASSAY Lipopolysaccharide (LPS) conjugated to trinitrophenol (TNP) and human serum albumin (HSA) conjugated to TNP were injected at 20 μg/mouse intraperitoneally into BNX mice and SCID mice, respectively, both of which had previously received 106 murine yolk sac cells intraperitoneally a month earlier. A second injection of the antigens was
performed one week later, animals were bled after seven days and sera assayed for the presence of specific antibodies.
A two-fold serial dilution of the mouse sera was made in microtiter plates. Sheep red blood cells (SRBC) coated with dinitrophenol (DNP) were added to each well. The plates were incubated at room temperature for one hour. The results of the assay were assessed visually. A diffused pattern of SRBC indicated a positive TNP-specific antibody response. Negative wells had a small, tight pellet of SRBC.
6.2. RESULTS
6.2.1. ISOLATION OF MURINE YOLK SAC CELLS
In the mouse, the yolk sac is fully formed by day 7 and blood island formation usually appears by day 8.5 of gestation. Therefore, in order to isolate homogeneous and undifferentiated yolk sac cells, mouse embryos were surgically removed prior to visible blood island formation, preferably at day 7 of gestation. The yolk sac region of the embryos was separated by excision, and the external surface of the yolk sac was immersed in cold EDTA which caused the detachment of the yolk sac cells from the membrane into a single cell suspension (FIG. 1) . When the physical appearance of yolk sac cells obtained from day 7 and day 8.5 embryos was compared by flow cytometry analysis, freshly isolated day 7 cells clearly displayed a much more uniform cell shape and cell size than the day 8.5 cells, suggesting that yolk sac cells were a homogeneous population at day 7 but by day 8.5, differentiative activities had already occurred to generate a mixed population of cells in the yolk sac (FIG. 2) . Therefore, day 7 yolk sac cells were used
for all in vitro and jLn vivo studies described herein, infra.
6.2.2. CELL SURFACE PHENOTYPE OF YOLK SAC CELLS
The freshly isolated yolk sac cells from day 7 mouse embryos were immediately examined for their cell surface expression of a number of known leukocyte markers by reactivity with monoclonal antibodies. 0 Such uncultured yolk sac cells express CD34 but not Thy-1, MHC class I and class II antigens (FIG. 3) . The expression of CD34 by yolk sac cells is consistent with them being primitive stem cells as CD34 is currently the earliest detectable marker on bone 5 marrow hematopoietic stem cells. The absence of MHC antigen expression at this stage is significant in that the likelihood of rejection of these cells by a genetically disparate host upon in vivo transfer is greatly reduced. Further, the lack of Thy-1 _ expression indicates that the yolk sac cells of the invention represent an earlier cell population in ontogeny than the Thy-1+ hematopoietic stem cells found in bone marrow, thus should contain a pluripotent population that is less committed to any 5 specific cell lineages.
6.2.3. LONG-TERM MAINTENANCE OF YOLK SAC CELLS The yolk sac cells isolated from day 7 embryos were established in culture in the presence of 0 leukemia inhibitory factor (LIF) at 10-100 U/ml without a feeder layer. The cells expanded in number, having a doubling time of about 18 hours. Such cultured cells have been grown in vitro for over 41 passages covering a period of time over nine months in continuous culture. Alternatively, yolk sac cells
could.also be grown in stem cell factor with similar results.
Although LIF is capable of suppressing differentiation of the yolk sac cells over an extended period of i vitro growth, the effect of LIF is incomplete because a small fraction of the cultured cells began to express certain differentiation markers including Thy-1 and MHC-encoded molecules. However, the majority of the long-term cultured cells retained their original cell surface phenotype. Further, such cells continued to be pluripotent as evidenced by their ability to give rise to mature blood cells in vitro and in vivo, infra. The cells with the original phenotype in long-term cultures may be obtained by cell sorting or by repeated limiting dilution cloning.
6.2.4. DIFFERENTIATION OF YOLK SAC CELLS IN VITRO After one month of in vitro culture in the presence of LIF, the yolk sac cells were tested for their ability to differentiate into mature blood cells of all lineages in response to various known hematopoietic growth factors including IL-3, IL-2, and EPO. When cultured in IL-3 and EPO, the appearance of red blood cells was readily detectable in the yolk sac cultures. In response to CSF's and IL-3, the yolk sac cells matured into megakaryocytes and granulocytes. Fig. 4 is a blood stain of a yolk sac culture grown in the presence of a combination of cytokines and the appearance of various blood cell lineages can be identified. In addition, the expression of various leukocyte surface markers by these cells became detectable, including CD34, CD45, LFA, MAC-1, Ly-1 and Ly-2.
6.2-5. DIFFERENTIATION OF YOLK SAC CELLS IN VIVO A long-term culture of yolk sac cells of BALB/c origin was injected into allogeneic C3H/SCID mice after 22 passages in vitro. Four weeks later, 5 spleens and livers of the treated animals were analyzed for the presence of donor cells by monoclonal antibodies.
The donor cells were identified by antibodies specific for the donor H-2d haplotype. 0 Double-staining experiments utilizing two antibodies further demonstrated that certain subpopulations of the donor cells expressed CD3, Thy-1, B220 and Ml/70 (FIG. 5) . Therefore, these results indicated that the long-term cultured mouse yolk sac cells were capable 5 of differentiating naturally in vivo into T cells, B cells and macrophages.
6.2.6. GENERATION OF IMMUNOCOMPETENT
CELLS BY YOLK SAC CELLS IN VIVO Q In order to examine whether the yolk sac cells could give rise to functionally mature blood cells, the long-term cultured yolk sac line was transferred in vivo into allogeneic SCID or BNX mice, and tested for specific antibody production. When the - BNX mice received yolk sac cells and subsequently were immunized with LPS a month later, specific antibody titers were detected in the sera (FIG. 6) . As LPS is a polyclonal B cell activating agent, this result shows the presence of functionally active 0 antibody-producing B cells. Additionally, when SCID mice were injected with yolk sac cells followed by HSA immunization, which is a T cell dependent antigen, an antibody response was again detectable, suggesting that long-term cultured yolk sac cells could 5 differentiate to become immuno-competent T and B cells in vivo.
6.2.7. YOLK SAC CELLS REPOPULATE
CHEMO-ABLATED MOUSE SPLEENS
Certain classes of chemotherapeutic drugs are effective, and have been used, as ablative agents for bone-marrow in bone-marrow transplantation procedures (Floersheim and Ruszkiewicz, 1969, Nature
222:854). One of the most effective agents used to replace whole body irradiation in bone-marrow transplantation procedures is the drug Busulfan (Tutschka et al. , 1987, Blood 70:1382). Through careful titration of the dose of Busulfan and the use of inbred lines of mice (C57BL/6) of a defined age and weight (3-4 weeks of age) , doses of Busulfan have been determined which fully ablate the bone-marrow of these mice but do not directly kill them. These doses of Busulfan result in the eventual death of the treated mice between 11 and 14 days if they do not receive transplanted bone-marrow. This dose is 65 mg of Busulfan/g of body weight administered in a single dose by I. . injection. When C57BL/6 mice were treated with this dose of Busulfan and then received an I.P. injection of 106 syngeneic cultured yolk-sac cells 24 hrs. following Busulfan treatment, the transplant recipients revealed spleen repopulation at day 7 and 14 post Busulfan treatment (FIG. 7) . On day 7, spleen colony formation within the recipient was observed, indicative of the initial stages of splenic repopulation by the transplant. Additionally, comparison at day 12 post treatment, of the spleens of control Busulfan treated mice not receiving yolk-sac transplants and those animals receiving transplants showed a marked difference in splenic viability. While the spleens of control animals were dark, almost black in color, and appeared necrotic, the spleens of transplant recipients displayed a red/pink color and appeared normal and healthy. Further, the survival
time of the yolk sac cell-treated mice was extended to between 18 and 20 days.
6.2.8. IN UTERO ADMINISTRATION OF YOLK SAC CELLS RESULTS IN TISSUE CHIMERISM
A long-term cultured yolk sac cell line was tested for its ability to survive in an allogeneic host. 10,000-50,000 BALB/c yolk sac cells after 13-20 passages in vitro were injected in utero in day 8 embryos of C57BL/6 mice. At birth, the spleens and livers of the neonates were harvested and analyzed for the presence of donor cells.
Since the donor cells were of the H-2d haplotype, a monoclonal antibody specific for H-2d antigens was used to identify the donor cells by flow cytometry analysis. FIG. 8 presents the results from two neonates examined and it clearly shows that donor cells were present in both the liver and spleen of the recipient mice in substantial numbers. Therefore, in utero administration of yolk sac cells into MHC-mismatched mice resulted in tissue chimerism, and survival and homing of the cells to the lymphohematopoietic organs. Tissue chimerism was retained when the mouse tissues were examined even one month after birth.
6.2.9. XENOGENEIC TRANSPLANTATION OF YOLK SAC CELLS RESULTS IN LONG-TERM PERSISTENCE OF CELLS IN VIVO
In order to test the feasibility of using yolk sac cells in xenogeneic transplantation and reconstitution, long-term cultured BALB/c yolk sac cells were injected into a newborn Hampshire sheep and a Nubian goat. The sheep received 40xl06 murine yolk sac cells intravenously at day 3 after birth and the
goat received the same cell dose at day 7 after birth. Four days later, both animals received a second dose of 200xl06 cells. After four additional days, a final injection of 60xl06 cells was given, the peripheral blood mononuclear cells were harvested for antibody staining and flow cytometry analysis about one and a half month later.
FIG. 9 demonstrates that a substantial number of blood cells obtained from the sheep were reactive with anti-H-2d antibody. While there were lower numbers of donors in the peripheral blood of the goat, donor cells were nonetheless detectable. In addition, cells expressing the murine T cell marker Ly-1 were also present from both animals. However, neither animal had cells that were positive for the murine macrophage marker Mac-l, consistent with the fact that macrophages are not normally present in the peripheral blood.
The results of this experiment are revealing in a number of ways. It illustrates the possibility of xenogeneic reconstitution using murine yolk sac cells. Neither animal was pre-treated with irradiation or cytotoxic drug. The high cell doses and the repetitive injections did not induce graft rejection. Both animals also appeared normal and healthy, having no indication of graft versus host reaction. The consistent finding of a high number of donor cells recoverable from the sheep than the goat may be a result of the goat being of an older age before receiving the first cell injection. The younger age of the sheep when it was given the first cell dose might have resulted in a more efficient induction of tolerance. However, there was still acceptance of the donor cells in the goat in the absence of any prior immunosuppressive treatment. If
induction of tolerance is the mechanism underlying this observation, this further suggests that the tolerized hosts may also accept other solid organs including the heart, liver and kidney from xenogeneic donors sharing the same haplotype of the original donors. Finally, the expression of a T cell marker indicates normal differentiation and maturation in vivo, and the absence of macrophages in the peripheral blood suggests the appropriate homing of the right cell lineages in the host upon intravenous administration of yolk sac cells.
7. EXAMPLE: IN VIVO TRANSFORMATION OF YOLK SAC CELLS In this example, both untransformed yolk sac cells and a retroviral vector containing the exogenous gene of interest are injected into the target animal. The exogenous gene used is the growth hormone gene (bGH) . Yolk sac cells harvested from day 8 C57/SJL mouse embryos are cultured on an STO feeder layer system until approximately 20 x 106 cells per culture flask (150 cm) were generated. Cells were passed to new flasks when the cell density became greater than 80%. All experiments were performed with cells at passage 10 or greater.
Newborn mice were injected I.P. with yolk sac cells (2-4 x 106) at 3 to 5 days of age. Two months (positive results have been observed with infections as early as two weeks following yolk sac injection) after I.P. injection of yolk sac cells, animals received lxlO6 viral particles of a replication deficient retroviral vector produced from the Moloney murine Leukemia Virus based Mulligan ψ2 packaging cell line after transformation with the plasmid pLJPCKbGH by I.V. injection into the tail vein.
Of 145 animals treated by this procedure, 112 were positive for bGH in the serum by ELISA assay. The following is a breakdown of the positive bGH levels of these test animals:
20-59 ng/ml = 56 mice 60-100 ng/ml = 20 mice 100-200 ng/ml = 14 mice 200-500 ng/ml = 13 mice > 500 ng/ml = 9 mice
An equal number of control animals were injected with the retroviral vector but not with the yolk sac cells. None of these were positive for bGH. It is believed that either the retroviral vector specifically can transfect the injected yolk sac cells, and/or the yolk sac cells secrete factors having an effect on the nearby cells, rendering them susceptible to transfection.
Claims
1. A cellular composition comprising a substantially homogeneous population of yolk sac stem cells displaying a phenotype of CD34+, Thy-1—, MHC class I" and MHC class II- which are capable of differentiating into mature blood cells in vivo.
2. The composition of Claim 1 wherein the yolk sac stem cells are isolated from a yolk sac prior to blood island formation.
3. The composition of Claim 2 wherein the yolk sac stem cells are isolated from a mouse yolk sac at day 7 of gestation.
4. The composition of Claim 2 wherein the yolk sac stem cells are isolated from a human yolk sac at day 10 of gestation.
5. A method of generating a cellular composition of yolk sac stem cells comprising isolating a substantially homogeneous population of yolk sac stem cells displaying a phenotype of CD34+, Thy-1-, MHC class I- and MHC class II-.
6. A method of expanding a cellular composition of yolk sac stem cells comprising culturing, in the presence of an agent which suppresses cellular differentiation, a substantially homogeneous population of yolk sac stem cells displaying a phenotype of CD34+, Thy-I-, MHC class I- and MHC class II-.
7. The method of Claim 6 wherein the agent is leukemia inhibiting factor.
8. The method of Claim 6 wherein the agent is stem cell factor.
9. A method of hematopoietic reconstitution comprising administering the yolk sac stem cells of Claim 1 to an animal.
10. The method of Claim 9 wherein the cellular composition is administered intravenously.
11. The method of Claim 9 wherein the cellular composition is administered in utero.
12. The method of Claim 9 wherein the animal is a mouse.
13. The method of Claim 9 wherein the animal is a sheep.
14. The method of Claim 9 wherein the animal is a goat.
15. The method of Claim 9 wherein the animal is a human.
16. The method of Claim 15 wherein the human is infected with the human immunodeficiency virus.
17. A non-human animal having a hematopoietic system reconstituted with yolk sac stem cells.
18. The animal of Claim 17 wherein the animal is a mouse.
19. The animal of Claim 17 wherein the animal is a sheep.
20. The animal of Claim 17 wherein the animal is a goat.
21. A method of producing blood cells in vitro t comprising culturing, in the presence of a growth factor, a substantially homogeneous population of yolk sac stem cells displaying a phenotype of CD34+, Thy-1-, MHC class I- and MHC class II- which are capable of differentiating into mature blood cells in vivo.
22. The method of Claim 21 wherein the growth factor is EPO, IL-2, IL-3, G-CSF, M-CSF, GM-CSF, or a combination thereof.
23. A method of producing blood cells in an animal comprising:
(a) injecting into an animal a substantially homogeneous population of yolk sac stem cells displaying a phenotype of CD34+, Thy-1—, MHC class I- and MHC class II- which are capable of differentiating into mature blood cells in vivo: and
(b) collecting blood cells from the animal.
24. A method of tolerizing an animal comprising administering a substantially homogeneous population of allogeneic or xenogeneic yolk sac stem cells displaying a phenotype of CD34+, Thy-1—, MHC class I- and MHC class II-.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73025091A | 1991-07-15 | 1991-07-15 | |
| US730250 | 1991-07-15 | ||
| US88037592A | 1992-05-08 | 1992-05-08 | |
| US880375 | 1992-05-08 | ||
| PCT/US1992/005918 WO1993002182A1 (en) | 1991-07-15 | 1992-07-14 | Yolk sac stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0594725A1 true EP0594725A1 (en) | 1994-05-04 |
| EP0594725A4 EP0594725A4 (en) | 1994-11-30 |
Family
ID=27112018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19920915474 Withdrawn EP0594725A4 (en) | 1991-07-15 | 1992-07-14 | Yolk sac stem cells. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0594725A4 (en) |
| JP (1) | JPH06508762A (en) |
| AU (1) | AU661709B2 (en) |
| CA (1) | CA2113555A1 (en) |
| WO (1) | WO1993002182A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744347A (en) * | 1987-01-16 | 1998-04-28 | Ohio University Edison Biotechnology Institute | Yolk sac stem cells and their uses |
| US5437766A (en) * | 1993-10-22 | 1995-08-01 | The Procter & Gamble Company | Multi-ply facial tissue paper product comprising biodegradable chemical softening compositions and binder materials |
| US5599705A (en) * | 1993-11-16 | 1997-02-04 | Cameron; Robert B. | In vitro method for producing differentiated universally compatible mature human blood cells |
| JP7488571B2 (en) * | 2018-11-08 | 2024-05-22 | インテグリカルチャー株式会社 | Animal cell proliferation promoter, animal cell culture medium and animal cell culture device |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4497796A (en) * | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
| US5032407A (en) * | 1987-01-16 | 1991-07-16 | Ohio University Edison Animal Biotechnology Center | Gene transfer using transformed, neodetermined, embryonic cells |
-
1992
- 1992-07-14 WO PCT/US1992/005918 patent/WO1993002182A1/en not_active Application Discontinuation
- 1992-07-14 JP JP5502931A patent/JPH06508762A/en active Pending
- 1992-07-14 CA CA002113555A patent/CA2113555A1/en not_active Abandoned
- 1992-07-14 EP EP19920915474 patent/EP0594725A4/en not_active Withdrawn
- 1992-07-14 AU AU23248/92A patent/AU661709B2/en not_active Ceased
Non-Patent Citations (2)
| Title |
|---|
| No further relevant documents disclosed * |
| See also references of WO9302182A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU661709B2 (en) | 1995-08-03 |
| JPH06508762A (en) | 1994-10-06 |
| WO1993002182A1 (en) | 1993-02-04 |
| EP0594725A4 (en) | 1994-11-30 |
| AU2324892A (en) | 1993-02-23 |
| CA2113555A1 (en) | 1993-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU701752B2 (en) | Yolk sac stem cells and their uses | |
| US6093531A (en) | Generation of hematopoietic cells from multipotent neural stem cells | |
| Srour et al. | Sustained human hematopoiesis in sheep transplanted in utero during early gestation with fractionated adult human bone marrow cells | |
| US5985660A (en) | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation | |
| Zanjani et al. | Transplantation of hematopoietic stem cells in utero | |
| US20030124091A1 (en) | Endothelial cell derived hematopoietic growth factor | |
| US6821513B1 (en) | Method for enhancing hematopoiesis | |
| Goan et al. | The severe combined immunodeficient-human peripheral blood stem cell (SCID-huPBSC) mouse: a xenotransplant model for huPBSC-initiated hematopoiesis | |
| JP2006122054A (en) | Population of cells enriched for myeloid and/or lymphoid progenitors, and methods of making and using | |
| US20030100107A1 (en) | Compositions and methods for generating differentiated human cells | |
| AU661709B2 (en) | Yolk sac stem cells | |
| US5972627A (en) | Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby | |
| EP0652943B1 (en) | Hematopoietic facilitatory cells and their uses | |
| Yeoman et al. | Development of CD4 and CD8 single positive T cells in human thymus organ culture: IL-7 promotes human T cell production by supporting immature T cells | |
| WO1998012304A1 (en) | Culture system for hematopoietic stem cells | |
| AU780468B2 (en) | Method for enhancing hematopoiesis | |
| Péault et al. | Haematopoietic stem cell emergence and development in the human embryo and fetus; perspectives for blood cell therapies in utero | |
| AU2003200256B2 (en) | Generation of hematopoietic cells from multipotent neural stem cells | |
| Yamagami | Exploiting molecules involved in fetal-maternal tolerance to overcome immunologic barriers | |
| Srour et al. | Sustained human hematopoiesis in sheep transplanted in utero during |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19940114 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
| RHK1 | Main classification (correction) |
Ipc: C12N 5/06 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19941013 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
| 17Q | First examination report despatched |
Effective date: 19970918 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19990430 |